Clinical Research & Development
Our Montreal facilities have been the birthplace of a number of key Wyeth
products, including Premarin®, a leading product in women's health
care for over 60 years and Rapamune®, an innovative drug for
transplant recipients.
Our Clinical R&D facility, opened in 1989, is located within the Montreal
manufacturing facilities and employs more than 50 people. Our clinical research
activities include work in osteoporosis and vasomotor symptoms of menopause,
hemophilia, schizophrenia and Alzheimer's disease, pain management, breast
cancer and kidney cancer, immunology, infectious diseases, asthma and arthritis
and vaccines. We are currently conducting trials on a number of promising
drugs, some examples include:
-
a vaccine to help prevent Alzheimer's disease and another to immunize infants
-
a molecule to prevent chronic constipation, which often occurs in patients who
are taking opium-based products for intense pain
-
a molecule to allow patients with kidney cancer to live longer.
Our Montreal clinical research facility is also the major co-ordination centre
for Wyeth clinical trials conducted in Canada. In 2008, we conducted trials in
more than 250 sites across all provinces in Canada and involved almost 1500
patients.
In addition to conducting our own clinical trials, we also invest heavily in
clinical research across Canada. In 2008, Wyeth contributed $10 million to
clinical research programs.
Clinical Supply
The Clinical Supply division in Montreal was established in 1990 with more than 20
employees and has grown in importance to 100 employees in 2009. This division
is responsible for preparing and supplying the clinical trial kits needed for
the majority of Wyeth's projects worldwide. In 2008, the Clinical Supply
division:
-
manufactured 9 million doses for use by patients enrolled in 40 clinical trials
around the world
-
provided 70% of the clinical trial supplies for Wyeth worldwide.
Chemical Development
The Chemical Development division, established in Montreal since the 1940's,
employs over 50 people, mostly university-educated chemists and engineers. The
division supports the discovery and development of new small molecules in Wyeth
Research, through supply of quality compounds and the development of chemical
processes. Early-development products are synthesized in laboratories, while
larger amounts required for pre-clinical studies are prepared in the scale-up
facility. Montreal scientists and staff contribute currently to the development
of innovative therapies for multiple sclerosis, atherothrombosis, women's
health diseases, mental health disorders, heart disease and cancer.
Français
